Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Ken_Drazan
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
synthetic biology
immunotherapy gene therapy |
| gptkbp:foundedIn |
2019
|
| gptkbp:founder |
gptkb:Sean_Parker
|
| gptkbp:fundedBy |
gptkb:Kleiner_Perkins
gptkb:University_of_California,_San_Francisco gptkb:Parker_Institute_for_Cancer_Immunotherapy gptkb:Westlake_Village_BioPartners |
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
ArsenalBio
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
engineered T cell therapies
|
| gptkbp:website |
https://www.arsenalbio.com/
|
| gptkbp:bfsParent |
gptkb:Alexandria_Venture_Investments
|
| gptkbp:bfsLayer |
6
|